By Elsie Kamsiyochi
A Chinese pharmaceutical conglomerate secured an unusual victory in Washington after hiring a lobbying firm closely connected to Donald Trump Jr., according to public filings and documents reviewed by Reuters.
What began as a commercial dispute between a Minnesota medical-device startup and one of its largest foreign investors ultimately evolved into a case that raised alarm among experts, lawmakers, and ethics specialists over the potential leverage Chinese companies may gain through political connections, especially within a U.S. administration already scrutinized for blurred lines between private relationships and public decision-making.
The dispute emerged when FastWave, a Minnesota-based startup that developed a catheter device powered by a regulated laser technology with potential military applications, sought to convince the Committee on Foreign Investment in the United States (CFIUS) to unwind a $12 million investment made by China’s Grand Pharmaceutical Group in 2021. FastWave initially embraced the partnership, but it grew increasingly uneasy as fundraising disputes intensified and as the company suspected its Chinese investor could be positioning itself to siphon away valuable intellectual property. The company pointed to a press release announcing Grand Pharma’s cooperation with a Chinese competitor as evidence of potential conflicts of interest.
FastWave hoped CFIUS would force Grand Pharma to divest its 40% stake or limit its influence by converting it to a passive investment. But instead, the company found itself weakened financially, struggling to raise capital due to Grand Pharma’s veto rights, and placing its hopes in a national security review that would ultimately get rejected. What followed was a chain of events that now forms the core of controversy surrounding this case.
Public records show that in December, Grand Pharma hired Checkmate, a lobbying outfit led by Ches McDowell, a North Carolina political operative known for his close relationship with Donald Trump Jr. Social media posts show the two hunting together, and property records reveal they co-own land in North Carolina. Grand Pharma paid Checkmate $30,000 for two weeks of work related to CFIUS issues—an unusually intense, high-cost engagement for such a brief period.
According to sources familiar with the matter, Checkmate helped arrange a meeting in early January between Grand Pharma’s attorney Jeff Bialos—a former Pentagon official—and Chris Pilkerton, who had just been confirmed to lead CFIUS.
FastWave, meanwhile, was unable to secure similar high-level access despite two attempts, and was given only calls with staff-level officials. Whether the meeting arranged by Checkmate influenced the outcome remains unknown, though experts say the optics highlight the advantages that well-connected lobbyists can provide, even in cases with national security implications.
Later that month, CFIUS formally rejected FastWave’s filing, citing “material misstatements” in the company’s submissions. The committee’s letter referenced contradictory statements about Grand Pharma’s behavior during fundraising discussions. FastWave strongly disputed the characterization, arguing that CFIUS never gave it an opportunity to clarify anything and that some alleged contradictions were simply misinterpretations of timing and context.
The startup said it had answered 29 sets of questions during a 200-day review period, only to be rejected at the last possible moment without any prior warning that its filings were considered flawed.
Notably, CFIUS did not address the national security risks FastWave claimed, nor did it assess whether Grand Pharma’s relationship with the Chinese competitor violated any agreements. This omission fueled further concerns among experts, including analysts from the Hudson Institute and lawmakers like Senator Elizabeth Warren.
They warned that the case could signal how foreign firms—particularly from China—might exploit personal or political networks to shape U.S. regulatory outcomes, especially in a high-stakes environment where technology, security, and geopolitics intersect.
The White House forcefully rejected any suggestion of impropriety. A spokesperson insisted CFIUS processes remain rigorous, impartial, and unaltered by political influence, calling speculation about favoritism “categorically false.” Checkmate, for its part, emphasized that McDowell himself did not work directly on the case, though filings list him as part of the team representing Grand Pharma. Bialos said the outcome rested solely on fact-based analysis, characterizing the issue as a private commercial dispute wrongly pushed into the national security arena.
However, FastWave now finds itself financially devastated, saying it cannot afford to refile with CFIUS even though that remains technically an option.
The company argues that the irregularities it encountered—unexpected procedural decisions, opaque communication, and a rejection letter focused on alleged inconsistencies rather than national security—effectively shut its doors at a critical moment. Experts note that outright rejection of CFIUS filings for reasons unrelated to national security is uncommon, heightening scrutiny of a process that typically affords companies opportunities to correct misunderstandings.
The saga also highlights the complicated relationships surrounding Trump’s political orbit. McDowell met Trump Jr. at a conservative gala in 2016, bonding over hunting and eventually forming a friendship that included shared trips and a jointly owned property. Images on social media show the two posing with rifles, falcons, and fellow high-profile conservatives.
Although there is no evidence that Donald Trump Jr. was personally involved in the Grand Pharma matter, the closeness between a foreign-influenced lobbying effort and the president’s family circle underscores a persistent concern: when political influence, private business, and national security collide, even the appearance of undue access can have far-reaching implications.
As scrutiny builds and lawmakers call for further transparency, the FastWave–Grand Pharma case has become more than a dispute over a medical device. It has become a litmus test for how foreign investors may seek to navigate Washington’s regulatory landscape, the power of personal networks in policymaking, and the challenges facing U.S. startups when confronting deep-pocketed firms backed by geopolitical rivals.
Whether the case prompts meaningful oversight reforms or simply becomes another footnote in the long history of Washington lobbying remains to be seen.
Source Reuters
Original article
Comments